Search

In a proof-of-concept study, researchers at MSK and the National Institutes of Health (NIH) have developed an artificial intelligence (AI) tool that uses routine clinical data, such as that from a simple blood test, to predict whether someone’s cancer will respond to immune checkpoint inhibitors, a type of immunotherapy drug that helps immune cells kill cancer cells.

… Monday, June 3, 2024 In a proof-of-concept study, researchers at Memorial Sloan Kettering Cancer Center (MSK) and the National Institutes of Health (NIH) have developed an artificial intelligence (AI) tool that uses routine clinical data, such as that from a simple blood test, to predict whether someone

The research identifies a protein called ENPP1 as a potential drug target in the treatment of advanced cancers with chromosome instability.

… Monday, December 28, 2020 Summary Researchers at Memorial Sloan Kettering have learned how chromosomal instability allows cancer cells to avoid immune defenses and metastasize (spread). The discovery opens up potential new avenues for treatment. Cancer cells are known for spreading genetic chaos. As

On August 5, 2022, the FDA approved the first targeted therapy for patients with HER2-low breast cancer that has spread to other parts of the body and is unable to be surgically removed. The drug, trastuzumab deruxtecan (T-DXd), was approved based on a clinical trial led by Memorial Sloan Kettering Cancer Center (MSK) breast medical oncologist Shanu Modi.

… Friday, August 5, 2022 On August 5, 2022, the FDA approved the first targeted therapy for patients with HER2-low  breast cancer  that has spread to other parts of the body and is unable to be surgically removed. The drug, trastuzumab deruxtecan (T-DXd), was approved based on a clinical trial led by Memorial

The multicenter project, which yielded dozens of scientific papers on more than 30 different kinds of cancer, has officially drawn to a close.

… Friday, January 4, 2019 Summary This wide-ranging effort, which was jointly funded by the National Human Genome Research Institute and the National Cancer Institute, has been completed. When The Cancer Genome Atlas (TCGA) launched in 2005, the understanding of the genetic changes that drive cancer was

Experts from Memorial Sloan Kettering presented some of the latest research on this challenging complication of many cancer surgeries.

… Friday, December 7, 2018 Summary Cancer-related lymphedema is one of the most challenging long-term side effects that can occur after cancer surgery. It can greatly impact a person’s quality of life. Cancer-related lymphedema is one of the most challenging long-term side effects that can occur after

Meet Paul Yoon, Program Coordinator of Spiritual Care at Memorial Sloan Kettering, who immigrated to the US from South Korea, survived cancer, and is navigating his concerns around violence against Asian Americans.

… Friday, May 28, 2021 Compassion for self and others can heal the wounds we carry. It’s a profound lesson that Paul Yoon ,  Program Coordinator of Spiritual Care at Memorial Sloan Kettering ,   has learned and embraced through some of his most difficult life experiences — from immigrating to the US from

A new study sheds light on a little understood biological process called quiescence, which enables blood-forming stem cells to exist in a dormant or inactive state in which they are not growing or dividing. According to the study's findings, researchers identified the genetic pathway used to maintain a cell's quiescence, a state that allows bone marrow cells to escape the lethal effects of standard cancer treatments.

… Friday, January 9, 2009 A new study sheds light on a little understood biological process called quiescence, which enables blood-forming stem cells to exist in a dormant or inactive state in which they are not growing or dividing. According to the study’s findings, researchers identified the genetic

The combination of nivolumab (Opdivo®) and ipilimumab (Yervoy®) has shown improved progression-free survival (PFS) compared with chemotherapy as a first-line treatment for people with a high tumor mutational burden (TMB) in advanced non-small cell lung cancer (NSCLC). Data from the CheckMate -227 trial is being reported by Matthew Hellmann, MD, of Memorial Sloan Kettering Cancer Center, at the AACR Annual Meeting 2018. This research is featured in the meeting’s press program, and findings are being presented in the Clinical Trials Plenary Session, “Immunotherapy Combinations: The New Frontier in Lung Cancer.”

… Monday, April 16, 2018 The combination of nivolumab (Opdivo ® ) and ipilimumab (Yervoy ® ) has shown improved progression-free survival (PFS) compared with chemotherapy as a first-line treatment for people with a high tumor mutational burden (TMB) in advanced non-small cell lung cancer (NSCLC). Data

New research funds have been awarded by the RSNA Research & Education Foundation to Robert Young, MD for Using Functional MRI and Diffusion Tensor Imaging of the Language Pathway to Optimize Brain Tumor Resection.

… Monday, June 13, 2011 New research funds have been awarded by the RSNA Research & Education Foundation to Robert Young, MD for  Using Functional MRI and Diffusion Tensor Imaging of the Language Pathway to Optimize Brain Tumor Resection .

Learn how a new cancer engineering PhD program is attracting leading scientists to come to MSK.

… Friday, September 13, 2024 A visionary new approach to solving problems in cancer science is now fully underway at Memorial Sloan Kettering Cancer Center (MSK), as the inaugural class begins  the Pat and Ian Cook Doctoral Program in Cancer Engineering . Leading researchers — drawn to MSK by the opportunity